Mark Coleman Sells 6,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman sold 6,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $230.30, for a total value of $1,381,800.00. Following the completion of the transaction, the director directly owned 35,140 shares in the company, valued at $8,092,742. This trade represents a 14.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Coleman also recently made the following trade(s):

• On Tuesday, June 2nd, Mark Coleman sold 5,537 shares of Axsome Therapeutics stock. The shares were sold at an average price of $223.39, for a total value of $1,236,910.43.
• On Friday, May 29th, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The shares were sold at an average price of $233.46, for a total value of $1,400,760.00.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $233.31 on Thursday. The firm has a market capitalization of $12.01 billion, a PE ratio of -62.55 and a beta of 0.61. The business’s fifty day moving average price is $199.79 and its 200 day moving average price is $177.40. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32. Axsome Therapeutics, Inc. has a 12 month low of $96.09 and a 12 month high of $238.56.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. Axsome Therapeutics’s revenue was up 57.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Axsome Therapeutics

Several large investors have recently bought and sold shares of the stock. Birchview Capital LP lifted its holdings in shares of Axsome Therapeutics by 1.0% during the fourth quarter. Birchview Capital LP now owns 6,061 shares of the company’s stock worth $1,107,000 after purchasing an additional 61 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Axsome Therapeutics by 3.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,921 shares of the company’s stock worth $351,000 after acquiring an additional 65 shares during the period. Xponance LLC increased its stake in shares of Axsome Therapeutics by 2.4% during the fourth quarter. Xponance LLC now owns 3,265 shares of the company’s stock worth $596,000 after acquiring an additional 76 shares during the period. Assetmark Inc. increased its stake in shares of Axsome Therapeutics by 7.2% during the first quarter. Assetmark Inc. now owns 1,182 shares of the company’s stock worth $200,000 after acquiring an additional 79 shares during the period. Finally, Allworth Financial LP increased its stake in shares of Axsome Therapeutics by 6.6% during the third quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock worth $175,000 after acquiring an additional 89 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Monday, April 20th. Robert W. Baird upped their price objective on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Wolfe Research assumed coverage on shares of Axsome Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $230.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Finally, Needham & Company LLC upped their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $251.26.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.